Search for new products by date added, alphabetically, or by pharmacological action.
New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules and peptides being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can. New products can be identified throughout the Tocris website by the New symbol.
If you can't find what you are looking for we welcome new product suggestions. If you would like to be kept informed about new products by email, please sign up for our monthly e-alert service.
| Cat. No. | Product Name / Activity | Date Added |
|---|---|---|
| 6903 | DPTIP | Jul 2019 |
| Potent and selective N-SMase2 inhibitor; brain penetrant | ||
| 6884 | TC SL C5 | Jul 2019 |
| Metastasis-associated lung adenocarcinoma transcript 1 (Malat1) RNA inhibitor | ||
| 6801 | Tocriscreen Epigenetics Library | Jul 2019 |
| A library of 101 epigenetic compounds (250 μL, 10 mM DMSO solutions) | ||
| 6790 | GSK 126 | Jul 2019 |
| Very high affinity and selective EZH2 inhibitor | ||
| 6960 | ABT 199 | Jul 2019 |
| Selective, high affinity Bcl-2 inhibitor; orally bioavailable | ||
| 6877 | VU 0134992 | Jul 2019 |
| Kir4.1 blocker | ||
| 6874 | AMG 333 | Jul 2019 |
| Potent and selective TRPM8 antagonist; active in vivo | ||
| 6908 | TR 14035 | Jul 2019 |
| Potent integrin α4β7 and α4β1 antagonist; orally bioavailable | ||
| 6934 | 673 A | Jun 2019 |
| Aldehyde dehydrogenase (ALDH1A) inhibitor; depletes CD133+ cancer stem cells (CSC) | ||
| 6957 | Reparixin L-lysine salt | Jun 2019 |
| Potent CXCR1 and CXCR2 allosteric antagonist | ||
| 6521 | I-BET 762 | Jun 2019 |
| Potent and high affinity BRD inhibitor; anti-inflammatory; orally bioavailable. | ||
| 6956 | Galunisertib | Jun 2019 |
| ALK4 and ALK5 (TGFβRI) inhibitor | ||
| 6966 | Thalidomide - linker 13 | Jun 2019 |
| Thalidomide-PEG1-ethylamine | ||
| 6887 | ML 335 | Jun 2019 |
| Selective K2P2.1 (TREK-1) and K2P10.1 (TREK-2) activator | ||
| 6561 | BAY 6035 | Jun 2019 |
| Potent and selective SMYD3 inhibitor | ||
| 6967 | Thalidomide - linker 14 | Jun 2019 |
| Thalidomide-PEG2-ethylamine | ||
| 6968 | Thalidomide - linker 15 | Jun 2019 |
| Thalidomide-alkylC6-amine | ||
| 6963 | Pomalidomide - linker 8 | Jun 2019 |
| Pomalidomide-PEG4-ethylamine | ||
| 6854 | LY 3009120 | Jun 2019 |
| Potent pan-Raf kinase inhibitor | ||
| 6948 | CRBN-6-5-5-VHL | Jun 2019 |
| Potent and selective cereblon degrader; cell-permeable | ||
| 6905 | Ceritinib | Jun 2019 |
| Highly potent ALK inhibitor; also potently inhibits IR, IGF1R, STK22D and FLT3 | ||
| 6716 | Pomalidomide - linker 4 | Jun 2019 |
| Pomalidomide-alkylC5-amine | ||
| 6713 | ZXH 3-26 | Jun 2019 |
| Potent and selective BRD4 degrader | ||
| 6489 | Ocean Blue, SE | Jun 2019 |
| Blue fluorescent dye; supplied as NHS ester | ||
| 6917 | Thalidomide - linker 9 | Jun 2019 |
| Thalidomide-alkylC4-amine | ||
| 6837 | GSK 923295A | May 2019 |
| Potent and selective centromere associated protein E (CENP-E) allosteric inhibitor | ||
| 6665 | BI 9321 | May 2019 |
| Nuclear receptor-binding SET domain (NSD) 3 antagonist; selectively binds PWWP1 domain | ||
| 6495 | AM 12 | May 2019 |
| TRPC5 inhibitor | ||
| 6433 | GSK 1016790A | May 2019 |
| Potent TRPV4 agonist; active in vivo | ||
| 6493 | A 317491 sodium salt | May 2019 |
| Selective, high affinity P2X3 and P2X2/3 receptor antagonist; antinociceptive | ||
| 6872 | BQCA | May 2019 |
| Positive allosteric modulator of M1 receptors | ||
| 6885 | PU 23 | May 2019 |
| Multidrug resistance protein (MRP) 4 inhibitor | ||
| 6926 | Fenoprofen calcium | May 2019 |
| Positive allosteric modulator of MC3 receptors; exhibits biased signaling | ||
| 6891 | PND 1186 | May 2019 |
| Potent FAK inhibitor; orally bioavailable | ||
| 6778 | S 38093 | May 2019 |
| Selective H3 antagonist and inverse agonist; antinociceptive | ||
| 6817 | BAY 8002 | May 2019 |
| Potent dual MCT1/2 inhibitor; orally bioavailable | ||
| 6861 | Anle138b | May 2019 |
| Oligomeric aggregation inhibitor; inhibits prion protein and α-synuclein aggregate formation | ||
| 6898 | Mitochondrial fusion promoter M1 | May 2019 |
| Mitochondrial fusion promoter | ||
| 6835 | ABT 737 | May 2019 |
| Bcl-2 family inhibitor; mimics BH3 and induces apoptosis in cancer cell lines | ||
| 6782 | Indisulam | May 2019 |
| Molecular glue; pre-mRNA splicing modulator | ||
| 6313 | A 33 | May 2019 |
| Potent and selective PDE4B inhibitor | ||
| 6882 | DiFMUP | May 2019 |
| Fluorescent phosphatase substrate | ||
| 6690 | Ceralifimod | May 2019 |
| Highly potent and selective S1P1 and S1P5 agonist | ||
| 6717 | FFN 270 | May 2019 |
| Fluorescent substrate for NET and VMAT2 | ||
| 6951 | Thalidomide - linker 12 | May 2019 |
| Thalidomide-PEG5-ethylamine | ||
| 6935 | GSK J5 HCl | May 2019 |
| Inactive isomer of GSK J4 (Cat. No. 4594); cell permeable | ||
| 6949 | Thalidomide - linker 10 | May 2019 |
| Thalidomide-alkylC2-amine | ||
| 6881 | SB 4 | May 2019 |
| Potent BMP4 agonist | ||
| 6815 | Selumetinib | May 2019 |
| Potent and selective MEK inhibitor; orally bioavailable | ||
| 6792 | Omipalisib | May 2019 |
| Highly potent PI 3-kinase inhibitor; also potent inhibitor of mTOR and DNA-PK | ||
| 5026 | KYT 0353 | May 2019 |
| Potent and selective inhibitor of L-type amino acid transporter 1 (LAT1); active in vivo | ||
| 6708 | SAH-EZH2 | May 2019 |
| EZH2/EDD interaction inhibitor; suppresses PCR2 complex function | ||
| 6771 | PHPS1 sodium salt | May 2019 |
| Shp2 (PTPN11) inhibitor | ||
| 6868 | 8-Azaadenosine | May 2019 |
| ADAR1 (adenosine deaminases acting on double-stranded RNA) inhibitor; inhibits leukemia stem cell self-renewal | ||
| 6845 | RCM 1 | May 2019 |
| FOXM1 inhibitor | ||
| 6840 | AD 01 | May 2019 |
| FKBPL (FK506-binding protein like)-based peptide; inhibits breast cancer stem cell self-renewal; also antiangiogenic | ||
| 6832 | Ec2la | May 2019 |
| Positive allosteric modulator of CB2 receptors; active in vivo | ||
| 6829 | (R)-Shikonin | May 2019 |
| PTEN inhibitor; induces necroptosis; anti-inflammatory | ||
| 6362 | GSK 143 | May 2019 |
| Syk inhibitor | ||
| 6749 | TH 5487 | Apr 2019 |
| Selective 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor | ||
| 6378 | JMS 17-2 hydrochloride | Apr 2019 |
| CX3CR1 antagonist | ||
| 6907 | VH 032 - linker 12 | Apr 2019 |
| VH 032-PEG2-amine | ||
| 6867 | Rhein | Apr 2019 |
| FTO (mRNA N6-methyladenine demethylase) inhibitor; also inhibits ALKBH2 and ALKBH3 | ||
| 6763 | AVE 1625 | Apr 2019 |
| Potent and selective CB1 receptor antagonist | ||
| 6679 | VH 032 - linker 4 | Apr 2019 |
| VH 032-PEG3-CH2CH2COOH | ||
| 6355 | VU 0650991 | Apr 2019 |
| Non-competitive GLP-1 antagonist; orally bioavailable and brain penetrant | ||
| 6434 | DFHO | Apr 2019 |
| Mimic of RFP fluorophore for imaging RNA in living cells | ||
| 6852 | VH 032 - linker 7 | Apr 2019 |
| VH 032-alkylC2-amine | ||
| 6762 | Urolithin A | Apr 2019 |
| PI 3-K/Akt/mTOR signaling inhibitor; blocks phosphorylation of Akt and p70S6K in vitro | ||
| 6740 | Siramesine hydrochloride | Apr 2019 |
| High affinity σ agonist (σ2 > σ1) | ||
| 6575 | StRIP16 | Apr 2019 |
| Rab8a GTPase-binding stapled peptide | ||
| 6510 | LNT 1 | Apr 2019 |
| Potent flap endonuclease 1 (FEN1) inhibitor; induces DNA damage response | ||
| 6814 | Sorafenib | Apr 2019 |
| Potent Raf-1 inhibitor; also inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and cKIT | ||
| 6864 | Ticagrelor | Apr 2019 |
| High affinity and reversible P2Y12 antagonist; displays inverse agonism in vitro; also inhibits ENT1 | ||
| 6634 | Surfen | Apr 2019 |
| Heparin sulfate antagonist | ||
| 6451 | Pexacerfont | Apr 2019 |
| Potent and selective CRF1 antagonist; anxiolytic | ||
| 6813 | Ibrutinib | Apr 2019 |
| Potent and selective BTK inhibitor | ||
| 6806 | AZ 3451 | Apr 2019 |
| Potent negative allosteric modulator of PAR2 | ||
| 6785 | E 7820 | Apr 2019 |
| α2 integrin inhibitor; anti-angiogenic | ||
| 6853 | VH 032 - linker 8 | Apr 2019 |
| VH 032-alkylC6-amine | ||
| 6856 | α-Mangostin | Apr 2019 |
| Inhibits proliferation and induces apoptosis selectively in pancreatic CSCs and cancer cell lines | ||
| 6744 | TL 13-12 | Apr 2019 |
| Selective ALK degrader | ||
| 6747 | TL 13-22 | Apr 2019 |
| Negative control for TL 13-12 | ||
| 6745 | TL 13-112 | Apr 2019 |
| Selective ALK Degrader | ||
| 6748 | PRX 07034 | Apr 2019 |
| Potent and selective 5-HT6 antagonist | ||
| 6746 | TL 13-110 | Apr 2019 |
| Negative control for TL 13-112 | ||
| 6502 | Janelia Fluor® 549, Tetrazine | Apr 2019 |
| Cell permeable yellow fluorescent dye; supplied as a tetrazine for 'click' chemistry | ||
| 6811 | Lapatinib | Apr 2019 |
| Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor | ||
| 6246 | BF 738735 | Apr 2019 |
| Potent and selective PI 4-kinase IIIβ inhibitor; broad spectrum enterovirus replication inhibitor | ||
| 5862 | ARN 14686 | Apr 2019 |
| Potent N-acylethanolamine acid amidase inhibitor; NAAA activity-based protein profiling (ABPP) probe | ||
| 6890 | VH 032 - linker 11 | Apr 2019 |
| VH 032-AlkylC8-Amine | ||
| 6865 | uPSEM 792 hydrochloride | Apr 2019 |
| Highly potent PSAM4-GlyR and PSAM4-5-HT3 chimeric ion channel agonist; brain-penetrant | ||
| 6880 | VH 032 - linker 10 | Apr 2019 |
| VH 032-alkylC10-amine | ||
| 6879 | VH 032 - linker 9 | Apr 2019 |
| VH 032-PEG1-amine | ||
| 6766 | AC 1903 | Mar 2019 |
| Selective TRPC5 blocker | ||
| 6866 | uPSEM 817 tartrate | Mar 2019 |
| Highly potent and selective uPSAM4-GlyR and PSAM4-5-HT3 chimeric ion channel agonist; brain-penetrant | ||
| 6784 | FTBMT | Mar 2019 |
| Potent and selective GPR52 agonist; orally bioavailable and BBB permeable | ||
| 6753 | CHS 828 | Mar 2019 |
| NAMPT inhibitor; active in vivo and cytotoxic | ||
| 6728 | RGFP 966 | Mar 2019 |
| Potent and selective HDAC3 inhibitor | ||
| 6818 | Artemether | Mar 2019 |
| Antimalarial; also inhibits neuroinflammation | ||
| 6787 | KI-7 | Mar 2019 |
| Positive allosteric modulator of A2B receptors | ||
| 6752 | LDC 000067 | Mar 2019 |
| Potent and selective CDK9 inhibitor | ||
| 6770 | ABT 639 | Mar 2019 |
| CaV3.2 and CaV3.1 channel blocker; orally bioavailable | ||
| 6830 | Conivaptan hydrochloride | Mar 2019 |
| Very high affinity vasopressin V1A and V2 antagonist; orally bioavailable | ||
| 6827 | Artesunate | Mar 2019 |
| Suppresses ROS-induced activation of the NLRP3 inflammasome; antimalarial | ||
| 6706 | DPNB-ABT 594 | Mar 2019 |
| Caged ABT 594; suitable for one- or two-photon photolysis | ||
| 6429 | ML 210 | Mar 2019 |
| Selectively kills mutant HRAS-expressing cells; glutathione peroxidase inhibitor; induces ferroptosis | ||
| 6490 | GNE 2861 | Mar 2019 |
| Group II PAK inhibitor; potently inhibits PAK4 and PAK 6 | ||
| 6819 | Mefloquine hydrochloride | Mar 2019 |
| Cx36 and Cx50 gap channel blocker; also antimalarial and antischistosomal | ||
| 1304 | BW-B 70C | Mar 2019 |
| 5-Lipoxygenase inhibitor | ||
| 6850 | Thalidomide - linker 6 | Mar 2019 |
| Thalidomide-alkylC2-Amine | ||
| 6754 | LJI308 | Mar 2019 |
| Potent pan-RSK inhibitor | ||
| 6605 | dTAG-13 | Mar 2019 |
| Degrades mutant FKBP12F36V fusion proteins; useful alternative to genetic methods for target validation | ||
| 6692 | WM 1119 | Mar 2019 |
| High affinity KAT6A (MOZ) competitive inhibitor | ||
| 6272 | KYP 2047 | Mar 2019 |
| High affinity prolyl oligopeptidase inhibitor; anti-angiogenic, neuroprotective and brain penetrant | ||
| 6834 | Auxin | Mar 2019 |
| Chemical dimerizer used in auxin-inducible degron (AID) system; phytohormone | ||
| 6812 | Afatinib dimaleate | Mar 2019 |
| Potent dual specificity EGFR/HER2 inhibitor; active in vivo | ||
| 6851 | Pomalidomide - linker 7 | Mar 2019 |
| Pomalidomide-alkylC2-amine | ||
| 6760 | Raphin 1 | Mar 2019 |
| Inhibitor of the regulatory subunit PPP1R15B of protein phosphatase 1; orally bioavailable and brain penetrant | ||
| 6755 | Darapladib | Mar 2019 |
| Potent lp-PLA2 inhibitor | ||
| 6664 | Kinesore | Mar 2019 |
| Kinesin-1 modulator; cell permeable | ||
| 6439 | JNJ 0966 | Mar 2019 |
| Pro-MMP9 activation inhibitor | ||
| 6816 | Sitagliptin phosphate | Feb 2019 |
| Potent and selective DPP IV inhibitor | ||
| 6798 | Click N-Acetylmuramic acid - alkyne | Feb 2019 |
| Bacterial peptidoglycan derivative; suitable for 'click'-conjugation to fluorescent dyes | ||
| 6702 | Cerulenin | Feb 2019 |
| Irreversible fatty acid synthase inhibitor | ||
| 6518 | BI 01383298 | Feb 2019 |
| Potent and selective SLC13A5 (Na+/citrate cotransporter) inhibitor | ||
| 6802 | 6 TMR Tre | Feb 2019 |
| Fluorescent trehalose; selectively labels mycobacterial cell envelope | ||
| 6809 | L-DON | Feb 2019 |
| Glutaminase inhibitor; also inhibits other glutamine-using enzymes and transporters | ||
| 6724 | CBA | Feb 2019 |
| Selective TRPM4 blocker | ||
| 6786 | BzF | Feb 2019 |
| Photoreactive unnatural amino acid; photo-crosslinker | ||
| 6759 | AA 147 | Feb 2019 |
| ER proteostasis regulator | ||
| 3719 | Talabostat mesylate | Feb 2019 |
| Potent DPP IV inhibitor; activates NLRP1b inflammasome | ||
| 6266 | Taxol Janelia Fluor® 646 | Feb 2019 |
| Red fluorescent taxol derivative | ||
| 6653 | FM19G11 | Feb 2019 |
| HIF α-subunit inhibitor | ||
| 6719 | YH 239-EE | Feb 2019 |
| Promotes survival of muscle stem cells (MuSCs); MDM2 inhibitor; activates p53 activity | ||
| 6597 | SPRi 3 | Feb 2019 |
| Potent sepiapterin reductase (SPR) inhibitor; attenuates proliferation of CD4+ T cells | ||
| 6793 | Dasatinib | Feb 2019 |
| Highly potent pan-Src/Bcr-Abl inhibitor | ||
| 6659 | sBADA | Feb 2019 |
| Green fluorescent D-amino acid for labeling peptidoglycans in bacteria | ||
| 6695 | CHIR 98014 | Feb 2019 |
| Highly potent and selective GSK-3 inhibitor | ||
| 6705 | Diminazene aceturate | Feb 2019 |
| ASIC blocker; antihyperalgesic | ||
| 6567 | RI-STAD 2 | Feb 2019 |
| AKAP disruptor; selectively binds PKA-RI with high affinity and blocks its interaction with AKAP; cell permeable | ||
| 6577 | Pyridone 6 | Feb 2019 |
| Potent pan-JAK inhibitor; induces intermediate mesoderm; cell-permeable | ||
| 6535 | NVP 2 | Feb 2019 |
| Potent and selective ATP-competitive CDK9 inhibitor | ||
| 6566 | STAD 2 | Feb 2019 |
| AKAP disruptor; selectively binds PKA-RII and blocks its interaction with AKAP; cell permeable | ||
| 6470 | A 410099.1 | Feb 2019 |
| High affinity XIAP antagonist; active in vivo | ||
| 6715 | A 71915 | Jan 2019 |
| Highly potent and competitive NPRA antagonist | ||
| 6644 | KuWal151 | Jan 2019 |
| Potent and selective CLK inhibitor | ||
| 6245 | SM 16 | Jan 2019 |
| Potent TGF-βRI inhibitor; orally bioavailable | ||
| 6668 | ML 184 | Jan 2019 |
| Selective GPR55 agonist; also promotes NSC proliferation and differentiation | ||
| 6621 | TFAX 488, TFP | Jan 2019 |
| Green fluorescent dye; amine reactive | ||
| 6774 | 16673-34-0 NLRP3i | Jan 2019 |
| NLRP3 inflammasome inhibitor | ||
| 6777 | TAK 375 | Jan 2019 |
| Very high affinity and selective melatonin receptor agonist | ||
| 6726 | T-peptide | Jan 2019 |
| Cytotoxic Tau peptide; cell permeable | ||
| 6709 | GSK 2018682 | Jan 2019 |
| S1P1 and S1P5 agonist | ||
| 6698 | ELA-11 (human) | Jan 2019 |
| High affinity apelin agonist | ||
| 6334 | THDOC | Jan 2019 |
| Positive modulator of GABAA receptors; endogenous neurosteroid | ||
| 6788 | Quizartinib | Jan 2019 |
| Highly potent FLT3 inhibitor | ||
| 6697 | ELA-21 (human) | Jan 2019 |
| High affinity apelin agonist | ||
| 6607 | dTRIM 24 | Jan 2019 |
| TRIM24 degrading PROTAC | ||
| 6553 | JF-NP-26 | Jan 2019 |
| Caged Raseglurant (Cat. No. 4416) | ||
| 5984 | LY 2955303 | Jan 2019 |
| High affinity and selective RARγ antagonist | ||
| 6598 | OD 36 hydrochloride | Jan 2019 |
| Potent RIP2 kinase inhibitor | ||
| 6606 | dBRD9 | Jan 2019 |
| Potent and selective BRD9 degrading PROTAC | ||
| 6243 | ML 385 | Jan 2019 |
| Nrf2 inhibitor; phenotypically lethal |